Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q1 FY21 Earnings Presentation
12 slides from Eris Lifesciences's earnings presentation, Aug 4, 2020
Slide 1: Exchange filing cover letter: Investor Presentation
Date: 04th August, 2020 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the requ
Slide 2: Eris Lifesciences Ltd Q1 FY21 Investor Presentation
ERIS LIFESCIENCES LTD Q1 FY 21 INVESTOR PRESENTATION 1
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 4: Market-Leading Growth in Core Cardio-Metabolic Franchise
Q1 FY 21 – MARKET-LEADING GROWTH IN CORE CARDIO-METABOLIC FRANCHISE Q1 21 yoy growth Covered Eris growth* June Eris % of Eris Revenue Market ’20 Cardio Metabolic + VMN 4% 8% 80% 20% Cardio Metabolic Segment 7% 13% 62% 25% VMN -7% -6% 18% 5% • Continued super-specialty focus and relentless execution
Slide 5: Continuing to Take Significant Share of Cardio-Metabolic Market Growth
CONTINUING TO TAKE SIGNIFICANT SHARE OF CARDIO-METABOLIC MARKET GROWTH Rank of companies by share of Q1 Market Growth in Rank of companies by share of June ‘20 Market Growth Cardio-Metabolic Covered Market in Cardio-Metabolic Covered Market Rank Company Share of CVM Growth Growth % Rank Company Shar
Slide 6: Resilience and Adaptability of Business Model Demonstrated
Q1 FY 21 – RESILIENCE AND ADAPTABILITY OF BUSINESS MODEL DEMONSTRATED DIGITAL REACH BUSINESS CONTINUITY • Innovative Initiatives • Proactive management of Covid related concerns, leading • ~ 40,000 doctors reached through digital channels to a highly motivated team and hence business continuity • Un
Slide 7: Guwahati Operations – Key Pillar of Business Model
Q1 FY 21 – GUWAHATI OPERATIONS – KEY PILLAR OF BUSINESS MODEL Guwahati plant now caters to 81% of revenue* Up from 76% in previous quarter Gross Profit Margins * Significant advantages in terms of control over quality 83.1% as well as costs 82.7% Q1 20 Q1 21 Tax as % of PBT As the plant enjoys incom
Slide 8: EHPL – New Products for Virus Resistance and General Hygiene
Q1 FY 21 – EHPL – NEW PRODUCTS FOR VIRUS RESISTANCE AND GENERAL HYGIENE • Q1 FY21 Revenue of INR 252.6 million with EBIDTA margin of 4% • EBIDTA breakeven achieved in the fourth month of new business launch Source: Unaudited Financial Statements 7
Slide 9: Standalone Income Statement
Q1 FY 21 – STANDALONE INCOME STATEMENT Consolidated Q1 FY 21 INR Millions Q1 FY21 Q1 FY20 yoy GR Sale of Products 2,561 2,598 -1.4% Other Operating Income 54 25 110.9% Revenue from Operations 2,615 2,623 -0.3% Gross Profit 2,174 2,171 0.1% Gross Profit Margin 83.1% 82.7% Employee Cost 524 448 17.0%
Slide 10: Consolidated Income Statement
Q1 FY 21 – CONSOLIDATED INCOME STATEMENT Consolidated Q1 FY 21 INR Millions Q1 FY21 Q1 FY20 yoy GR Sale of Products 2,881 2719 6.0% Other Operating Income 52 24 114.0% Revenue from Operations 2,932 2,743 6.9% Gross Profit 2,357 2,284 3.2% Gross Profit Margin 80.3% 83.3% Employee Cost 571 471 21.1% a
Slide 11: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors Others, FPI, 0.97% As on As on As on Sr no Name of Shareholder 30-Jun-20 31-Mar-20 31-Dec-19 10.11% 457.25* 368.9* 474* Promoters 55.55% 55.55% 56.23% 1 ChrysCapital (Emerald Investment Limited) 5.51% 5.51% 2.60% DIIS,
Slide 12: Thank You
THANK YOU ERIS LIFESCIENCES LTD KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 11